OCTREOSCAN Drug Patent Profile

Which patents cover Octreoscan, and what generic alternatives are available?

Octreoscan is a drug marketed by Curium and is included in one NDA.

The generic ingredient in OCTREOSCAN is indium in-111 pentetreotide kit. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetreotide kit profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Octreoscan

A generic version of OCTREOSCAN was approved as indium in-111 pentetreotide kit by SUN PHARM INDS INC on July 1^st, 2024.

Summary for OCTREOSCAN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	20
Patent Applications:	79
What excipients (inactive ingredients) are in OCTREOSCAN?	OCTREOSCAN excipients list
DailyMed Link:	OCTREOSCAN at DailyMed

Recent Clinical Trials for OCTREOSCAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alexander McEwan	Phase 1/Phase 2
AHS Cancer Control Alberta	Phase 1/Phase 2
AC Camargo Cancer Center	Phase 2

See all OCTREOSCAN clinical trials

US Patents and Regulatory Information for OCTREOSCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	OCTREOSCAN	indium in-111 pentetreotide kit	INJECTABLE;INJECTION	020314-001	Jun 2, 1994	AP	RX	Yes	Yes

Expired US Patents for OCTREOSCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Curium	OCTREOSCAN	indium in-111 pentetreotide kit	INJECTABLE;INJECTION	020314-001	Jun 2, 1994
Curium	OCTREOSCAN	indium in-111 pentetreotide kit	INJECTABLE;INJECTION	020314-001	Jun 2, 1994
Curium	OCTREOSCAN	indium in-111 pentetreotide kit	INJECTABLE;INJECTION	020314-001	Jun 2, 1994
Curium	OCTREOSCAN	indium in-111 pentetreotide kit	INJECTABLE;INJECTION	020314-001	Jun 2, 1994

International Patents for OCTREOSCAN

See the table below for patents covering OCTREOSCAN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	403476
Japan	H02184698	PEPTIDE DERIVATIVE
Luxembourg	87633
World Intellectual Property Organization (WIPO)	9304702
Italy	1244496	IMPIEGO TERAPEUTICO DEI PEPTIDI DELLA SOMATOSTATINA.

OCTREOSCAN Market Analysis and Financial Projection Experimental

Global Octreotide Market Dynamics and Financial Trajectory

Introduction to Octreotide

Octreotide, a synthetic peptide analog of somatostatin, is a crucial drug in the treatment of various medical conditions, including acromegaly, carcinoid syndrome, and certain types of tumors such as neuroendocrine tumors. Its mechanism of action involves inhibiting the release of growth hormones and other peptides, making it invaluable in managing symptoms and improving the quality of life for patients.

Market Size and Growth

The global octreotide market was valued at USD 2,711.77 million in 2023 and is expected to grow to USD 3,179.67 million by 2030, with a Compounded Annual Growth Rate (CAGR) of 2.3%[1].

Drivers of Market Growth

Rising Incidence Rates

The increasing incidence of conditions such as acromegaly, carcinoid syndrome, and neuroendocrine tumors drives the demand for octreotide. As the global population ages and the prevalence of these conditions rises, the market for octreotide is expected to expand[1].

Increasing Therapeutic Applications

Octreotide's broad therapeutic applications, beyond its traditional uses, are a significant driver. Research into new indications, such as polycystic ovary syndrome (PCOS) and certain cancers, is expanding its market appeal[3].

Technological Advancements

Advancements in biotechnology and the development of new formulations, such as sustained-release versions, enhance the efficacy and convenience of octreotide treatments. For example, Novartis AG's new sustained-release formulation of octreotide acetate has extended dosing intervals for patients with neuroendocrine tumors[1].

Growing Healthcare Spending

Global increases in healthcare spending are a major driver for the octreotide market. As healthcare systems invest more in infrastructure, pharmaceuticals, and patient care, the accessibility and demand for advanced treatments like octreotide increase[1].

Geographical Segmentation

Dominant Regions

North America and Europe dominate the octreotide market due to well-established healthcare systems, robust research and development initiatives, and a high prevalence of conditions treated by octreotide. These regions account for a significant share of the market, with North America holding 41.2% and Europe holding 30% of the global somatostatin analogs market[3].

Emerging Markets

The Asia-Pacific region is experiencing rapid growth, driven by increasing healthcare investments, expanding patient populations, and rising awareness of advanced treatment options. Countries like China, India, and Japan are key contributors to this growth. Latin America and the Middle East & Africa regions also present emerging opportunities, supported by improving healthcare infrastructure and growing investments in healthcare technologies[1].

Recent Developments

New Formulations and Approvals

Recent developments include the launch of new formulations and regulatory approvals. For instance, Novartis AG launched a new sustained-release formulation of octreotide acetate in 2023, and Ipsen Pharma received FDA approval for a new indication of octreotide acetate in treating acromegaly in 2024[1].

Market Segmentation

By Type

Octreotide is a major segment within the somatostatin analogs market, commanding a 55% share due to its broad applicability across various indications, including acromegaly, neuroendocrine tumors (NETs), and emergency settings for acute variceal bleeds[3].

By End Use

The market is segmented by end use, with hospitals, clinics, and research institutions being key consumers. The increasing adoption of octreotide in these settings is driven by its efficacy in managing complex medical conditions.

Financial Trajectory

Market Value

The global octreotide market is part of the larger somatostatin analogs market, which is forecasted to reach approximately USD 11.4 billion by 2033, growing at a CAGR of 6.1% from 2024 to 2033[3].

Revenue Streams

The revenue streams for octreotide are diverse, including sales from pharmaceutical companies, hospital and clinic treatments, and research applications. The expansion into new therapeutic areas and emerging markets is expected to enhance these revenue streams.

Challenges and Opportunities

Challenges

Despite the growth potential, the octreotide market faces challenges such as high treatment costs and limited accessibility in some regions. For example, treatments like Lutathera, which is used for unresectable or metastatic pancreatic neuroendocrine tumors, can be costly, with a monthly cost of approximately $23,333 per patient[5].

Opportunities

The focus on rare diseases and the pursuit of orphan drug designations present significant opportunities. Pharmaceutical companies are leveraging orphan drug status to develop novel treatments, which drives innovation and market growth. The expansion into emerging markets and the exploration of new therapeutic applications also offer substantial growth opportunities[3].

Analyst Viewpoint

From an analyst viewpoint, the dominance of acromegaly and neuroendocrine tumors in the market underscores the critical role of somatostatin analogs, including octreotide, in managing endocrine and gastrointestinal disorders. The market's growth trajectory reflects increasing prevalence rates, advancements in diagnostic techniques, and the efficacy of these medications in improving patient outcomes[3].

Key Takeaways

• Market Growth: The global octreotide market is expected to grow from USD 2,711.77 million in 2023 to USD 3,179.67 million by 2030.
• Dominant Regions: North America and Europe lead the market, with the Asia-Pacific region showing rapid growth.
• Therapeutic Applications: Octreotide's broad applicability across various indications drives its market share.
• Financial Trajectory: Part of the larger somatostatin analogs market, expected to reach USD 11.4 billion by 2033.
• Challenges and Opportunities: High treatment costs and limited accessibility are challenges, while the focus on rare diseases and emerging markets offer opportunities.

FAQs

What is the current market size of the global octreotide market?

The global octreotide market was valued at USD 2,711.77 million in 2023[1].

What is the expected CAGR of the global octreotide market from 2023 to 2030?

The global octreotide market is expected to grow at a CAGR of 2.3% from 2023 to 2030[1].

Which regions dominate the octreotide market?

North America and Europe dominate the octreotide market, with the Asia-Pacific region showing rapid growth[1][3].

What are the key drivers of the octreotide market?

Key drivers include rising incidence rates, increasing therapeutic applications, technological advancements, and growing healthcare spending[1][3].

What are the challenges faced by the octreotide market?

Challenges include high treatment costs and limited accessibility in some regions[5].

What opportunities are available for the octreotide market?

Opportunities include the focus on rare diseases, expansion into emerging markets, and the exploration of new therapeutic applications[3].

Sources

1. Global Octreotide Market | Growth | Share | Size | Trends and Forecast: Reanin Report Store.
2. SIGNA™ - GE Healthcare: GE Healthcare.
3. Somatostatin Analogs Market Size, Share, Growth | CAGR of 6.1%: Market Research Biz.
4. Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%: GlobeNewswire.
5. Lutetium (177Lu) Oxodotreotide (Lutathera) - Canada's Drug Agency: CADTH.